Eyes treated with Yutiq experienced lower recurrence rates of noninfectious uveitis than sham-treated eyes in a 36-month phase 3 trial, EyePoint Pharmaceuticals announced in a press release.
The second double-masked, randomized, phase 3 trial enrolled 153 patients in India, with 101 eyes receiving Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg) and 52 eyes receiving sham injections.
The recurrence rate of those treated with Yutiq was 46.5% compared with 75% for those treated with sham (P = .001). In addition, 8.9% of Yutiq-treated eyes needed the assistance of adjunctive
Uncategorized